Tilia Fiduciary Partners Inc. Invests $2.05 Million in Thermo Fisher Scientific Inc. (NYSE:TMO)

Tilia Fiduciary Partners Inc. bought a new position in Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) during the first quarter, according to its most recent disclosure with the SEC. The institutional investor bought 4,119 shares of the medical research company's stock, valued at approximately $2,050,000. Thermo Fisher Scientific accounts for about 1.4% of Tilia Fiduciary Partners Inc.'s holdings, making the stock its 29th biggest holding.

A number of other hedge funds and other institutional investors have also recently modified their holdings of TMO. LaFleur & Godfrey LLC grew its position in Thermo Fisher Scientific by 9.1% during the 4th quarter. LaFleur & Godfrey LLC now owns 29,767 shares of the medical research company's stock valued at $15,486,000 after purchasing an additional 2,488 shares during the last quarter. Brighton Jones LLC grew its position in Thermo Fisher Scientific by 28.9% during the 4th quarter. Brighton Jones LLC now owns 4,409 shares of the medical research company's stock valued at $2,293,000 after purchasing an additional 988 shares during the last quarter. Union Bancaire Privee UBP SA purchased a new stake in Thermo Fisher Scientific during the 4th quarter valued at about $71,877,000. Revolve Wealth Partners LLC boosted its holdings in shares of Thermo Fisher Scientific by 4.2% during the 4th quarter. Revolve Wealth Partners LLC now owns 491 shares of the medical research company's stock valued at $255,000 after acquiring an additional 20 shares during the last quarter. Finally, Leo Wealth LLC boosted its holdings in shares of Thermo Fisher Scientific by 1.5% during the 4th quarter. Leo Wealth LLC now owns 1,946 shares of the medical research company's stock valued at $1,012,000 after acquiring an additional 29 shares during the last quarter. 89.23% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently issued reports on the stock. Argus dropped their price target on shares of Thermo Fisher Scientific from $620.00 to $470.00 and set a "buy" rating on the stock in a report on Tuesday, April 29th. Robert W. Baird lowered their price objective on shares of Thermo Fisher Scientific from $603.00 to $573.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Royal Bank of Canada lowered their price objective on shares of Thermo Fisher Scientific from $651.00 to $637.00 and set an "outperform" rating on the stock in a research note on Thursday, April 24th. Scotiabank lowered their price objective on shares of Thermo Fisher Scientific from $650.00 to $605.00 and set a "sector perform" rating on the stock in a research note on Friday, April 25th. Finally, Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Wednesday, May 21st. Four investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $605.30.

Insiders Place Their Bets

In other news, EVP Gianluca Pettiti sold 300 shares of the business's stock in a transaction on Monday, April 28th. The shares were sold at an average price of $429.93, for a total transaction of $128,979.00. Following the completion of the sale, the executive vice president now directly owns 23,167 shares of the company's stock, valued at approximately $9,960,188.31. The trade was a 1.28% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction on Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the sale, the senior vice president now directly owns 10,816 shares of the company's stock, valued at $5,759,736.32. This represents a 25.87% decrease in their ownership of the stock. The disclosure for this sale can be found here. 0.33% of the stock is owned by insiders.

Thermo Fisher Scientific Trading Up 0.9%

Thermo Fisher Scientific stock opened at $401.99 on Friday. The stock has a market cap of $151.75 billion, a P/E ratio of 24.32, a PEG ratio of 2.99 and a beta of 0.78. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.66 and a quick ratio of 1.29. Thermo Fisher Scientific Inc. has a 1 year low of $390.50 and a 1 year high of $627.88. The firm's 50 day moving average price is $420.74 and its 200-day moving average price is $495.81.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its quarterly earnings results on Wednesday, April 23rd. The medical research company reported $5.15 earnings per share for the quarter, topping the consensus estimate of $5.10 by $0.05. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. The company had revenue of $10.36 billion for the quarter, compared to analysts' expectations of $10.23 billion. During the same quarter in the previous year, the business posted $5.11 earnings per share. Thermo Fisher Scientific's quarterly revenue was up .2% on a year-over-year basis. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, July 15th. Shareholders of record on Friday, June 13th will be paid a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.43%. The ex-dividend date is Friday, June 13th. Thermo Fisher Scientific's payout ratio is 10.09%.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.